Cargando…

Soluble urokinase-type plasminogen activator receptor is a novel biomarker predicting acute exacerbation in COPD

BACKGROUND: Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory condition, and progresses with acute exacerbations. (AE). During AE, levels of acute phase reactants such as C-reactive protein (CRP) and inflammatory cells in the circulation increase. Soluble urokinase-type plasmino...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gumus, Aziz, Altintas, Nejat, Cinarka, Halit, Kirbas, Aynur, Hazıroglu, Muge, Karatas, Mevlut, Sahin, Unal
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4334296/ https://www.ncbi.nlm.nih.gov/pubmed/25709430 http://dx.doi.org/10.2147/COPD.S77654

Ejemplares similares

A novel biomarker in the diagnosis of parapneumonic effusion: neutrophil gelatinase-associated lipocalin
por: Gümüs, Aziz, et al.
Publicado: (2014)

Soluble urokinase plasminogen activator receptor predicts mortality in exacerbated COPD
por: Godtfredsen, Nina S., et al.
Publicado: (2018)

Copeptin: a new predictor for severe obstructive sleep apnea
por: Çınarka, Halit, et al.
Publicado: (2015)

Association of Serum Magnesium Levels with Frequency of Acute Exacerbations in Chronic Obstructive Pulmonary Disease: A Prospective Study
por: Gumus, Aziz, et al.
Publicado: (2014)

Soluble urokinase-type plasminogen activator receptor as a measure of treatment response in acute exacerbation of COPD
por: AboEl-Magd, Gehan Hassan, et al.
Publicado: (2018)

Soluble Urokinase-Type Plasminogen Activator Receptor and Arterial Stiffness in Patients with COPD
por: Böcskei, Renáta M., et al.
Publicado: (2019)

In situ thrombosis in pulmonary arterial aneurysms due to Behçet’s disease and efficacy of ımmunosuppressive therapy
por: Ozkaya, Sevket, et al.
Publicado: (2012)

Soluble Urokinase Plasminogen Activator Receptor and Venous Thromboembolism in COVID‐19
por: Luo, Shengyuan, et al.
Publicado: (2022)

Right sided arcus aorta as a cause of dyspnea and chronic cough
por: Ozkaya, Sevket, et al.
Publicado: (2012)

Evaluation of Urokinase Plasminogen Activator Receptor, Soluble Urokinase Plasminogen Activator Receptor, and β1 Integrin in Patients with Hodgkin's Lymphoma
por: Kouhpayeh, Shirin, et al.
Publicado: (2017)

Soluble Urokinase Plasminogen Activator Receptor as a Marker for Use of Antidepressants
por: Haastrup, Eva, et al.
Publicado: (2014)

Soluble urokinase plasminogen activator receptor for the prediction of ventilator-associated pneumonia
por: van Oort, Pouline M., et al.
Publicado: (2019)

Kinetics of the soluble urokinase plasminogen activator receptor (suPAR) in cirrhosis
por: Garnæs, Emilie, et al.
Publicado: (2019)

Soluble urokinase plasminogen activator receptor level in individuals of advanced age
por: Wlazel, Rafal N., et al.
Publicado: (2020)

Soluble Urokinase Plasminogen Activator Receptor as a Diagnostic and Prognostic Biomarker in Cardiac Disease
por: Velissaris, Dimitrios, et al.
Publicado: (2021)

Plasma Soluble Urokinase Plasminogen Activator Receptor in Children with Urinary Tract Infection
por: Wittenhagen, Per, et al.
Publicado: (2011)

A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease
por: Spinale, Joann M., et al.
Publicado: (2014)

The Prognostic Significance of Soluble Urokinase Plasminogen Activator Receptor in Acute Myeloid Leukemia
por: Erkut, Nergiz, et al.
Publicado: (2016)

Clinical and prognostic usefulness of soluble urokinase plasminogen activator receptor in hemodialysis patients
por: Wlazeł, Rafał Nikodem, et al.
Publicado: (2018)

Circulating Soluble Urokinase-Type Plasminogen Activator Receptor in Obstructive Sleep Apnoea
por: Bocskei, Renata Marietta, et al.
Publicado: (2020)

Soluble urokinase plasminogen activator receptor (suPAR) in the emergency department: An update
por: Velissaris, Dimitrios, et al.
Publicado: (2022)

Soluble urokinase plasminogen activation receptor - An emerging new biomarker of cardiovascular disease and critical illness
por: Cyrille, Nicole B., et al.
Publicado: (2016)

Soluble Urokinase Plasminogen Activator Receptor (suPAR) as a Biomarker of Systemic Chronic Inflammation
por: Rasmussen, Line Jee Hartmann, et al.
Publicado: (2021)

Soluble urokinase plasminogen activator receptor: from biomarker to active participant in atherosclerosis and cardiovascular disease
por: Goodchild, Traci T., et al.
Publicado: (2022)

Soluble Urokinase Plasminogen Activator Receptor as a Decision Marker for Early Discharge of Patients with COVID-19 Symptoms in the Emergency Department
por: Stauning, Marius Ahm, et al.
Publicado: (2021)

Soluble Urokinase Receptor and the Kidney Response in Diabetes Mellitus
por: Dande, Ranadheer R., et al.
Publicado: (2017)

Association between serum soluble urokinase-type plasminogen activator receptor and atrial fibrillation
por: Ichihara, Noboru, et al.
Publicado: (2017)

Serum soluble urokinase plasminogen activator receptor in adolescents: interaction of chronic pain and obesity
por: Raff, Hershel, et al.
Publicado: (2020)

Clinical value of soluble urokinase type plasminogen activator receptors in chronic kidney disease
por: Ahmed, Reem M., et al.
Publicado: (2019)

Detection of soluble urokinase type plasminogen activator receptors in children with gingivitis and normal subjects
por: El‑Patal, Mohamed Abd‑Ellatif, et al.
Publicado: (2022)

Increased soluble urokinase plasminogen activator levels modulate monocyte function to promote atherosclerosis
por: Hindy, George, et al.
Publicado: (2022)

Prevalence of Occupational Asthma and Respiratory Symptoms in Foundry Workers
por: Kayhan, Servet, et al.
Publicado: (2013)

From lactate to soluble urokinase plasminogen activator receptor: The journey for ideal cardiac biomarker: Are we there in 2016?
por: Kapoor, Poonam Malhotra
Publicado: (2016)

Value of soluble Urokinase plasminogen activator receptor over age as a biomarker of impaired myocardial relaxation
por: Koh, Angela S., et al.
Publicado: (2017)

Soluble Urokinase Plasminogen Activator Receptor Levels in Tuberculosis Patients at High Risk for Multidrug Resistance
por: Mardining Raras, Tri Yudani, et al.
Publicado: (2012)

Full-length soluble urokinase plasminogen activator receptor down-modulates nephrin expression in podocytes
por: Alfano, Massimo, et al.
Publicado: (2015)

Soluble Urokinase Plasminogen Activator Receptor and the Risk of Coronary Artery Disease in Young Chinese Patients
por: Huang, Yuli, et al.
Publicado: (2017)

Soluble urokinase plasminogen activation receptor and long-term outcomes in persons undergoing coronary angiography
por: Sommerer, Claudia, et al.
Publicado: (2019)

Serum soluble urokinase plasminogen activator receptor (suPAR) in adults with growth hormone deficiency
por: Höybye, Charlotte, et al.
Publicado: (2019)

Soluble Urokinase Plasminogen Activator Receptor (suPAR) Concentrations Are Elevated in Patients with Neuroendocrine Malignancies
por: Özdirik, Burcin, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ciapfbohpi4b4t280868soqd26